# Eli Lilly and Company Investment Analysis: Evaluating the Future of Pharmaceutical Innovation

> This comprehensive research report evaluates Eli Lilly and Company (LLY), focusing on its dominant position within the global pharmaceutical sector. The analysis provides a deep dive into the company's business model, management efficacy, and future growth drivers, including its robust pipeline in metabolic and neurological health. By exploring various risk factors and potential market scenarios, this thesis offers investors a strategic look at the long-term potential of one of the world's leading healthcare innovators.

**Companies**: Eli Lilly and Company Common Stock
**Sectors**: Pharmaceuticals
**Published**: 2026-07-22
**Last Updated**: 2026-07-22
**Source**: https://thesisloop.ai/thesis/eli-lilly-and-company-investment-analysis-evaluating-the-future-of-893cf6bd-3489-4f02-92a6-c4281b74bcc2

## Score Overview

| Company | Management | Business Model | Future Growth | Risk |
|---------|-----------|---------------|--------------|------|
| Eli Lilly and Company Common Stock | 53/100 | 78/100 | 66/100 | 64/100 |

## Eli Lilly and Company Common Stock (NYSE:LLY)

**Sector**: Pharmaceuticals | **Industry**: Pharmaceuticals

### Management Credibility

- **[CATALYST] Pharmaceuticals M&A and Portfolio Action** (NEUTRAL): The company has entered into acquisition agreements with potential payments of up to $12 billion at closing. — target: $12 billion
  > As part of our business development activities in 2026, we have entered into acquisition agreements, subject to closing conditions. Potential amounts payable at closing for these pending acquisitions would be up to approximately $12 billion.
- **[CATALYST] Pharmaceuticals Product or Capex Inflection** (POSITIVE, IN_PROGRESS): Capital expenditures have increased significantly, with $5.29 billion spent on property and equipment in the first nine months of 2025 compared to $3.56 billion in the prior year period, confirming the commitment to higher spend for manufacturing expansion. (2 in progress across 2 tracked commitments)
  > Production increases and delivery presentation initiatives are ongoing, and additional capacity is expected to be operational over the next several years.
- **[METRIC] Pharmaceuticals Balance Sheet Resilience** (NEUTRAL, REVISED): The estimated unfunded commitment has been slightly adjusted to $878 million (from $868 million previously) to be paid over the next 10 years. (1 revised across 1 tracked commitment)
  > As of September 30, 2025, we had approximately $878 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.
- **[METRIC] Pharmaceuticals Free Cash Flow** (POSITIVE, REVISED): The unfunded commitment target was lowered to $850 million, indicating a reduction in future cash outflow obligations. (1 revised across 1 tracked commitment)
  > while decreasing income tax payments during the second half of 2025.
- **[METRIC] Pharmaceuticals Margin Profile** (POSITIVE, REVISED): Management has raised the full-year effective tax rate guidance to 19.8% for the first nine months of 2025, up from the previously guided 19%, primarily due to the unfavorable tax impacts of non-deductible acquired IPR&D charges and the enactment of the OBBBA. (1 revised across 1 tracked commitment)
  > The effective tax rates were 22.8 percent and 19.8 percent for the three and nine months ended September 30, 2025, respectively... As a result of the OBBBA, the effective tax rates for the three and nine months ended September 30, 2025 were unfavorably impacted by incremental tax expense recognized 
- **[METRIC] Pharmaceuticals Revenue Growth** (NEGATIVE, REVISED): The company recognized a $200.0 million sales-based milestone for Jardiance during the current period and confirmed eligibility for up to $410.0 million more in 2026. (1 in progress, 3 revised across 4 tracked commitments)
  > As of September 30, 2025, we have the right to receive up to $410.0 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.
- **[PRINCIPLE] Pharmaceuticals Capital Allocation** (POSITIVE, IN_PROGRESS): The company continued to execute its share repurchase program, spending $2.60 billion in the first nine months of 2025, leaving $12.40 billion remaining as of September 30, 2025. (2 in progress across 2 tracked commitments)
  > As of March 31, 2026, we had approximately $850 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.
- **[PRINCIPLE] Pharmaceuticals Revenue Quality** (NEUTRAL): The company expects to receive a share of net sales for the Jardiance product family through the end of 2028 based on product performance. — target: Share of net sales (+2 more commitments)
  > For the Jardiance product family in the most significant markets, which remains in the collaboration through December 31, 2028, we receive a share of net sales depending on performance of the product
- **[TREND] Pharmaceuticals Policy and Regulation** (NEUTRAL): Management intends to adopt the new expense disaggregation accounting standard for the fiscal year ending December 31, 2027. — target: Adoption of ASU 2024-03 (+4 more commitments)
  > We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2027.
- **[TREND] Pharmaceuticals Supply Chain Reconfiguration** (NEGATIVE, REVISED): The potential liability for contract manufacturing and supply agreements has increased to approximately $9 billion, up from the previously reported $8 billion. (1 revised across 1 tracked commitment)
  > Executed agreements related to our medicines in development could, under certain circumstances, require us to pay up to approximately $8 billion if we do not purchase specified amounts of goods or services over the durations of the agreements, which are generally up to 8 years.

### Business Model

- **[METRIC] Pharmaceuticals Balance Sheet Resilience** (POSITIVE, Change: EXPANDING): The company utilized its balance sheet for significant M&A, acquiring NexPharm in May 2024 and announcing the $1.0 billion acquisition of Verve Therapeutics in July 2025. (3 shifted, 1 expanding)
  > Potential amounts payable at closing for these pending acquisitions would be up to approximately $12 billion... we had a total of $10.1 billion of unused committed bank credit facilities
- **[METRIC] Pharmaceuticals Revenue Growth** (POSITIVE, Change: EXPANDING): Cardiometabolic Health revenue grew 73% year-over-year for the six months ended June 30, 2025, driven by massive volume growth in Mounjaro and Zepbound, though partially offset by lower realized prices. (5 expanding across 3 engines)
  > Total cardiometabolic health: 2026 Total $15,760; 2025 Total $9,208
- **[PRINCIPLE] Pharmaceuticals Competitive Moat** (POSITIVE, Change: EXPANDING): The moat is strengthening through clinical pipeline expansion, including Phase 3 initiations for tirzepatide in type 1 diabetes and positive Phase 3 results for orforglipron in obesity. (4 expanding)
  > Mounjaro and Zepbound accounted for 65 percent of our total revenue for the three months ended March 31, 2026, and we expect cardiometabolic health products will continue to represent a significant and growing portion of our business
- **[PRINCIPLE] Pharmaceuticals Revenue Quality** (POSITIVE, Change: EXPANDING): The U.S. market remains the dominant revenue source, growing 43% due to high demand for obesity and diabetes treatments, despite pricing pressures. (2 expanding)
  > We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.
- **[TREND] Pharmaceuticals Demand Cycle** (NEUTRAL): International markets (Outside U.S.) are growing rapidly, with revenue increasing 81% year-over-year, largely due to the expansion of Mounjaro into China and other major markets.
  > Outside U.S. $7,680; Revenue $19,799; Percent Change 81

### Future Growth

- **[CATALYST] Pharmaceuticals M&A and Portfolio Action** (NEUTRAL): Lilly acquired Ventyx Biosciences for $1.1 billion to gain access to new oral therapies for inflammatory diseases, strengthening its future product lineup.
  > In March 2026, we acquired all shares of Ventyx Biosciences, Inc. (Ventyx) for a purchase price of $14.00 per share in cash (or an aggregate of $1.1 billion, net of cash acquired).
- **[CATALYST] Pharmaceuticals Product or Capex Inflection** (POSITIVE, Trend: ACCELERATING): Lilly is significantly increasing its capital investment to address demand-supply imbalances for incretins. Expenditures for long-lived assets increased 43% year-over-year, and management explicitly stated that additional capacity is expected to be operational over the next several years to resolve periodic unavailability. (2 accelerating, 3 steady across 5 signals, 2 leading indicators)
  > To support anticipated demand for our current and prospective products, we have undertaken significant manufacturing expansion initiatives. Additional capacity is expected to become operational over the next several years.
- **[METRIC] Pharmaceuticals Margin Profile** (POSITIVE, Trend: ACCELERATING): R&D investment is accelerating to support a late-stage pipeline of ~50 candidates. YTD R&D spending rose 18% to nearly $8 billion, reflecting a strategic shift toward long-term portfolio durability over short-term margin expansion. (2 accelerating, 1 steady across 3 signals)
  > Research and development expenses increased 28 percent for the three months ended March 31, 2026, driven by continued investments in our early and late-stage portfolio.
- **[METRIC] Pharmaceuticals Revenue Growth** (POSITIVE, Trend: ACCELERATING): Revenue growth for the incretin portfolio is accelerating significantly, driven by the massive scale-up of Mounjaro and the successful launch of Zepbound. Mounjaro revenue grew from $979.7 million in Q2 2023 to $3.09 billion in Q2 2024, while Zepbound contributed $1.24 billion in its first full year of launch. (5 accelerating across 5 signals, 1 leading indicator)
  > Mounjaro and Zepbound accounted for 65 percent of our total revenue for the three months ended March 31, 2026
- **[PRINCIPLE] Pharmaceuticals Capital Allocation** (POSITIVE, Trend: ACCELERATING): R&D investment is accelerating as the company advances its late-stage pipeline, particularly in cardiometabolic health and neuroscience. R&D expenses rose 15% in the three-month period and 21% for the six-month period year-over-year, reflecting a deliberate strategy to reinvest high gross margins into future growth. (2 accelerating across 2 signals)
  > Research and development expenses increased 15 percent and 21 percent for the three and six months ended June 30, 2024, respectively, driven by continued investment in our portfolio and our people.
- **[PRINCIPLE] Pharmaceuticals Unit Economics** (POSITIVE, Trend: ACCELERATING): R&D investment is accelerating as the company advances its late-stage pipeline. R&D expenses grew 23% in Q2 2025 and 16% for the first half of 2025, reflecting increased investment in early and late-stage portfolios to sustain long-term growth. (1 accelerating across 1 signal)
  > Research and development expenses increased 23 percent and 16 percent for the three and six months ended June 30, 2025, respectively, driven by continued investments in our early and late-stage portfolio.
- **[TREND] Pharmaceuticals Demand Cycle** (POSITIVE, Trend: NEW_TREND): While the document notes the impact of the Inflation Reduction Act (IRA) and government price setting for products like Jardiance starting in 2026, the specific 'Bridge Program' for Medicare obesity access is a forward-looking regulatory and market access shift currently in the planning/implementation phase. (2 new trend across 2 signals)
  > In August 2023, HHS selected Jardiance... as one of the first ten medicines subject to government-set prices effective in 2026
- **[TREND] Pharmaceuticals Policy and Regulation** (POSITIVE, Trend: NEW_TREND): While the Inflation Reduction Act (IRA) creates long-term pricing pressure, the company is navigating new market structures. Specifically, the selection of Jardiance for Medicare price negotiations starting in 2026 represents a new regulatory trend that will impact customer access and net pricing. (4 new trend across 4 signals)
  > Under the Medicare GLP-1 Bridge program (Bridge Program), Medicare beneficiaries will have access to discounted Lilly obesity medicines by July 1, 2026 through December 31, 2027

### Risk Assessment

- **[CATALYST] Pharmaceuticals M&A and Portfolio Action** (NEGATIVE, Risk: HIGH): The risk is intensifying as the company completed or announced several billion-dollar acquisitions in Q2 and July 2025, including NexPharm ($924.7M), Verve (up to $1.3B), and SiteOne (up to $1.0B), while total debt increased by $6.26 billion since year-end 2024. (1 intensifying)
  > Potential amounts payable at closing for these pending acquisitions would be up to approximately $12 billion.
- **[CATALYST] Pharmaceuticals Product or Capex Inflection** (NEGATIVE, Risk: MODERATE): The risk is stable as the company continues to aggressively expand capacity to meet demand that previously exceeded production in 2024. Capital expenditures for long-lived assets reached $3.5 billion for the first half of 2025. (2 stable, 2 intensifying)
  > To support anticipated demand for our current and prospective products, we have undertaken significant manufacturing expansion initiatives. Additional capacity is expected to become operational over the next several years.
- **[METRIC] Pharmaceuticals Balance Sheet Resilience** (NEUTRAL): Balance sheet risk is intensifying as total debt increased by $8.86 billion since year-end 2024 to $42.51 billion, primarily to fund acquisitions like Morphic and Scorpion. (1 intensifying, 1 easing, 1 stable)
  > As of September 30, 2025, total debt was $42.51 billion, an increase of $8.86 billion compared with $33.64 billion as of December 31, 2024.
- **[METRIC] Pharmaceuticals Margin Profile** (NEGATIVE, Risk: HIGH): Pricing pressure is intensifying; U.S. realized prices fell 15% in the third quarter, a significant acceleration from the previously reported 7% decline. (2 intensifying)
  > Revenue increased for the three months ended March 31, 2026, driven primarily by increased volume, partially offset by lower realized prices... Price (7)% [in the U.S.]
- **[METRIC] Pharmaceuticals Revenue Growth** (NEUTRAL): The risk remains stable but significant; U.S. realized prices fell by 8% in the first half of 2025, primarily driven by Mounjaro and Zepbound, despite massive volume growth. (1 stable)
  > In the U.S. for the three and six months ended June 30, 2025, the volume increase and the lower realized prices were driven by Zepbound and Mounjaro. ... Price (8)% [for U.S. 2025 vs 2024].
- **[PRINCIPLE] Pharmaceuticals Competitive Moat** (NEUTRAL, Risk: LOW): The risk is stable; management continues to monitor the sale of counterfeit and compounded incretins and is pursuing legal action where appropriate. (4 stable)
  > We continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins. These practices may impact patient safety and undermine regulatory drug approval processes.
- **[PRINCIPLE] Pharmaceuticals Regulatory Position** (NEGATIVE, Risk: MODERATE): The risk is stable but ongoing; product liability litigation related to Mounjaro, Trulicity, and Zepbound has been coordinated into a federal Multidistrict Litigation (MDL) in Pennsylvania. (1 stable, 1 intensifying)
  > Since August 2023, various plaintiffs have filed lawsuits against us... alleging various injuries following purported use of incretin medicines, including Mounjaro, Trulicity, and Zepbound.
- **[PRINCIPLE] Pharmaceuticals Revenue Quality** (NEGATIVE, Risk: HIGH): Concentration risk remains high but stable; combined revenue for Mounjaro and Zepbound reached $10.1 billion for the quarter, representing approximately 57% of total revenue, slightly down from the 65% previously noted but still dominant. (2 stable, 1 intensifying, 1 high-severity)
  > Mounjaro and Zepbound accounted for 65 percent of our total revenue for the three months ended March 31, 2026
- **[PRINCIPLE] Pharmaceuticals Unit Economics** (NEUTRAL): Pricing pressure is stable but significant. U.S. realized prices dropped by 10% in 2025, primarily driven by Mounjaro and Zepbound rebates. (1 stable)
  > In the U.S., the volume increase and the lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound... Price (10)% [in the U.S.].
- **[TREND] Pharmaceuticals Market Structure** (NEUTRAL): The risk is stable as litigation continues. A U.S. District Court ruled against Lilly's cash replenishment model in May 2025, which the company is now appealing. (1 stable)
  > The U.S. District Court for the District of Columbia agreed with HRSA in May 2025 that the government must preapprove Lilly’s cash replenishment model, which HRSA has not done. Lilly appealed that decision to the U.S. Court of Appeals.
- **[TREND] Pharmaceuticals Policy and Regulation** (NEGATIVE, Risk: HIGH): The risk is intensifying as new legislation (OBBBA) enacted in July 2025 further implements spending cuts to federal healthcare programs like Medicaid and the Affordable Care Act, while the IRA's government-set prices for Jardiance take effect in 2026. (5 intensifying, 1 high-severity)
  > In August 2023, HHS selected Jardiance... as one of the first ten medicines subject to government-set prices effective in 2026. In January 2026, HHS selected Trulicity and Verzenio as additional medicines subject to government-set prices to be effective in 2028.

### Scenario Analysis

- Eli Lilly's core business is the development and commercialization of pharmaceutical products, which is fundamentally driven by clinical trial success, regulatory approvals, and healthcare demand rather than the AI infrastructure cycle. While the company may utilize AI tools for drug discovery or internal operations, it does not have a structural dependency on hyperscaler capex, semiconductor supply chains, or data center power demand, making its exposure incidental rather than core. (NEUTRAL)
- A shift toward lower rates reduces the equity discount rate, causing a significant re-rating of Lilly’s long-duration biotech pipeline and GLP-1 growth prospects. This first-order change in capital costs flows into a second-order strategic advantage, allowing the company to aggressively acquire smaller biotech firms like Ventyx and Morphic at more attractive valuations. Ultimately, this results in a third-order structural shift where Lilly consolidates its leadership in the metabolic drug market by out-investing competitors in manufacturing capacity and R&D while others are constrained by financing costs. (POSITIVE)
  > Interest expense $ 332 [2026] $ 244 [2025] ... As of March 31, 2026, total debt was $43.4 billion, an increase of $0.9 billion compared with $42.5 billion as of December 31, 2025.
- The scenario triggers a massive first-order shift toward domestic manufacturing, which Lilly is already leading through multi-billion dollar investments in API and parenteral facilities. This reshoring mitigates the second-order risk of supply chain disruptions and 200% potential tariffs on imported medicines, though it necessitates a significant increase in working capital to maintain safety stocks. Ultimately, this results in a third-order structural shift where Lilly’s valuation becomes increasingly tied to its 'policy visibility' and ability to navigate the intersection of US industrial policy and the Inflation Reduction Act's pricing controls. (POSITIVE)
  > the impact of global macroeconomic conditions, including... trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related 

---
*Generated by [ThesisLoop](https://thesisloop.ai) — AI investment research for US equities.*